Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Hutchinson-Gilford Progeria Syndrome (HGPS) Market Grown from 2024 to 2025?
In recent times, the market size for Hutchinson-Gilford Progeria Syndrome (HGPS) has seen robust growth. It is projected to expand from $97.63 billion in 2024 to $106.56 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.1%. Factors contributing to growth in the preceding period include heightened awareness of uncommon genetic conditions, an increase in funding allocated to progeria research, the expansion of genetic testing facilities, more government-led initiatives for rare diseases, and a global rise in the prevalence of genetic disorders.
What Growth Rate Is Anticipated for the Hutchinson-Gilford Progeria Syndrome (HGPS) Market in the Coming Years?
Expectations are high for the Hutchinson-Gilford Progeria Syndrome (HGPS) market, with a significant expansion anticipated in the coming years. By 2029, the market is projected to reach a hefty $149.22 billion, boasting a compound annual growth rate (CAGR) of 8.8%. Factors contributing to this impressive growth during the forecasted period include an uptick in funding for the exploration and development of new treatments, a surge in the incidence of progeria, increasing global healthcare expenditure, growing acceptance of cutting-edge therapeutic strategies, and an increased emphasis on early diagnosis. Technological progression, the creation of targeted therapies, advances in next-generation sequencing (NGS) technologies, the discovery of biomarkers, and improvements in drug delivery systems will also play key roles in shaping the market trend during this period.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21205&type=smp
Who Are the Leading Companies in the Hutchinson-Gilford Progeria Syndrome (HGPS) Market?
Major companies operating in the hutchinson-gilford progeria syndrome (HGPS) market are National Institutes of Health (NIH), Mount Sinai, Johns Hopkins Hospital, Duke University, Mayo Foundation for Medical Education and Research, Cleveland Clinic, Children’s Hospital of Philadelphia, St. Jude Children’s Research Hospital, Cincinnati Children’s Hospital Medical Center, University of Maryland, Boston Children’s Hospital, Children’s Hospital Los Angeles, Harvard Medical School, The Scripps Research Institute, Blueprint Genetics, Medicover Hospitals, Sentynl Therapeutics, UCSF Helen Diller Family Comprehensive Cancer Center, Progeria Research Foundation, AnGes MG Inc., PRG Science & Technology Co. Ltd.
What Are the Key Drivers of the Hutchinson-Gilford Progeria Syndrome (HGPS) Market?
Expectations are high for the growth of the hutchinson-gilford progeria syndrome (HGPS) market, driven primarily by an increase in funding for the research and development of fresh treatment procedures. Research & Development funding tends to apply to investments dedicated to the progression, enhancement and discovery of scientific information and technological resolutions. Such an increase in funding can be credited to factors such as escalating demand for innovative medication strategies and governmental contributions towards developments in healthcare. This enhanced financial support for research and development has a positive effect on the growth of solutions for hutchinson-gilford Progeria Syndrome by aiding in clinical trials and aiding the development of ground-breaking treatments. It can further boost progress in uncovering the genetic roots of this condition and aid the creation of targeted solutions. For instance, the Office for National Statistics revealed in April 2024, that in 2022, the UK government’s research and development expenditure shot up by 10.5% to £15.5 billion ($17.59), a significant rise from the previous year’s £14.0 billion ($15.88). Hence, the surge in research and development funding for innovative treatments is fuelling the growth of the hutchinson-gilford progeria syndrome (HGPS) market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21205&type=smp
What Are the Key Market Segments in the Hutchinson-Gilford Progeria Syndrome (HGPS) Industry?
The hutchinson-gilford progeria syndrome (HGPS) market covered in this report is segmented –
1) By Treatment Type: Farnesyltransferase Inhibitors (Zokinvy (Lonafarnib)), Low-dose Aspirin, Physical And Occupational Therapy, Hearing Aids, Genetic Counseling, Other Treatment Types
2) By Route Of Administration: Oral, Injectable, Intravenous, Transdermal
3) By Mechanism Of Action: Antisense Oligonucleotides, Crispr-cas9 Gene Editing, Rna Interference, Targeted Drug Delivery Systems
4) By End-User: Hospitals, Specialty Clinics, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Farnesyltransferase Inhibitors (Zokinvy (Lonafarnib)): Monotherapy With Lonafarnib, Combination Therapy With Other Drugs
2) By Low-dose Aspirin: Cardiovascular Protection, Anti-inflammatory Therapy
3) By Physical And Occupational Therapy: Mobility Support And Rehabilitation, Joint And Bone Health Management, Adaptive Equipment For Daily Activities
4) By Hearing Aids: Conventional Hearing Aids, Bone-Anchored Hearing Aids (BAHA), Cochlear Implants
5) By Genetic Counseling: Family Genetic Testing, Genetic Risk Assessment, Prenatal Counseling And Guidance
6) By Other Treatment Types: Stem Cell Therapy, Gene Editing and Therapy, Nutritional Support And Management
What Are the Latest Trends in the Hutchinson-Gilford Progeria Syndrome (HGPS) Market?
Prominent enterprises functioning in the hutchinson-gilford progeria syndrome (HGPS) market are pivoting towards the creation of more advanced farnesyltransferase inhibitors in an effort to enhance the effectiveness of treatment and mitigate the progression of the disease in patients. These inhibitors are medications designed to block the enzyme farnesyltransferase, which plays a crucial role in modifying proteins and hindering uncontrolled cell growth and aging. For example, in July 2022, the European Commission granted marketing permission to Eiger BioPharmaceuticals, an American biopharmaceutical company, for Zokinvy – the first and only authorized treatment for hutchinson-gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PL) targeted at children and young adults in Europe. Clinical trials have demonstrated that Zokinvy, an orally administered agent capable of modifying the disease, can reduce death risk in children by 72% and increase lifespan by approximately 4.3 years. This centralized marketing authorization awarded by the European Commission is recognized by all 27 EU member states, including Iceland, Liechtenstein, and Norway.
Access The Full Report Here:
What Are the Key Regional Markets in the Hutchinson-Gilford Progeria Syndrome (HGPS) Industry?
North America was the largest region in the hutchinson-gilford progeria syndrome (HGPS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hutchinson-gilford progeria syndrome (HGPS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21205
This Report Delivers Insight On:
1. How big is the hutchinson-gilford progeria syndrome (hgps) market, and how is it changing globally?
2. Who are the major companies in the hutchinson-gilford progeria syndrome (hgps) market, and how are they performing?
3. What are the key opportunities and risks in the hutchinson-gilford progeria syndrome (hgps) market right now?
4. Which products or customer segments are growing the most in the hutchinson-gilford progeria syndrome (hgps) market?
5. What factors are helping or slowing down the growth of the hutchinson-gilford progeria syndrome (hgps) market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model